Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Decreased Activity and Genetic Polymorphisms of CYP2C19 in Behçet's Disease.

Basic & clinical pharmacology & toxicology - 1 Oct 2017

Goktas Mustafa Tugrul, Karaca Ragip Ozgur, Kalkisim Said, Cevik Lokman, Kilic Levent, Akdogan Ali, Babaoglu Melih O, Bozkurt Atilla, Bertilsson Leif, Yasar Umit

Abstract excerpt

Behçet's disease (BD) is a systemic autoimmune disorder. Cytochrome P450 enzymes (CYPs) are responsible for various drug metabolism reactions as well as those of endogenous substances which may be associated with autoimmune disease susceptibility. Recently, we reported that in patients with BD, CYP2C9 seems to be down-regulated due to inflammation. In the same Turkish patients with BD, we investigated whether...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to 2-Pyridinylmethylsulfinylbenzimidazoles
Share to Anti-Inflammatory Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Behcet Syndrome

Share to Biotransformation

Share to Colchicine

Share to Cytochrome P-450 CYP2C19

Share to Hydroxylation

Share to Lansoprazole

Source

Identifiers

PMID: 27875029
DOI: 10.1111/bcpt.12710

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Decreased Activity and Genetic Polymorphisms of CYP2C19 in Behçet's Disease.PMID 27875029Read ↗

Lower CYP2C9 activity in Turkish patients with Behçet's disease compared to healthy subjects: a down-regulation due to inflammation?Semantic proximity Read ↗

CYP2C19 polymorphism has no correlation with the efficacy and safety of thalidomide in the treatment of immune-related bowel disease.Semantic proximity Read ↗

Evaluation of the relationship between polymorphisms in CYP2C19 and the pharmacokinetics of omeprazole, pantoprazole and rabeprazole.Semantic proximity Read ↗

MDR1 gene polymorphisms may be associated with Behçet's disease and its colchicum treatment response.Semantic proximity Read ↗

Analysis of the Potential Association of Drug-Metabolizing Enzymes CYP2C9*3 and CYP2C19*3 Gene Variations With Type 2 Diabetes: A Case-Control Study.Semantic proximity Read ↗

Inflammation altered correlation between CYP2C19 genotype and CYP2C19 activity in patients receiving voriconazole.Semantic proximity Read ↗

Genetic Polymorphism of CYP2C19 gene in the Stanislas cohort. A link with inflammation.Semantic proximity Read ↗

Limited frequency of the CYP2C19*17 allele and its minor role in a Japanese population.Semantic proximity Read ↗

The impact of the CYP2D6 gene polymorphism on the risk of pemphigoid.Semantic proximity Read ↗

Association between the methylene tetrahydrofolate reductase gene C677T mutation and colchicine unresponsiveness in Behcet's disease.Semantic proximity Read ↗

Impact of CYP2C19 genotype on voriconazole exposure and effect of voriconazole on the activity of CYP3A in patients with haematological malignancies.Semantic proximity Read ↗

Hydroxylation index of omeprazole in relation to CYP2C19 polymorphism and sex in a healthy Iranian population.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.